And yet no BP is knocking down their door and now rather surprising we're being advised towards the mid tier segment where they have mid tier distribution.
Talk about trial and error on the job. Indeed, P3 is now NO certainty given what they agreed to with the FDA with Phase 1. Previously I was an advocate given it would provide a look through. NOW it doesn't.
All IMO
PAR. SP, page-808
-
- There are more pages in this discussion • 167 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $104.9M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 29.5¢ | $89.62K | 294.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20607 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 16773 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |